The Risk-Benefit Dialogue: Sharing Decisions on Treatment and Considering Toxicity in High-Risk, Clinically Localized Prostate Cancer
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
For high-risk, clinically localized prostate cancer—a condition in which treatment choice is strongly driven by toxicity considerations—studies demonstrate wide variation in how clinicians describe side effects, often resulting in failure to mention or quantify information about potential harms. Without structured and transparent discussions, patients cannot fully engage in shared decision-making, and treatment regret and dissatisfaction are more likely. Data strongly support the meaningful impact of toxicity discussion during SDM on patient consultations.
Fields of Study & Subjects
Patient-Provider Communication in Healthcare
Prostate Cancer Diagnosis and Treatment
Palliative Care and End-of-Life Issues
Publication details
- Journal / source
- Default Digital Object Group
- Publication date
- 26 March 2026
- Language
- EN
- Document type
- Dataset